Eptifibatide (Integrilin, Millennium Pharmaceuticals, also co-promoted by Schering-Plough/Essex), is an antiplatelet drug of the glycoprotein IIb/IIIa inhibitor class.
Millennium Development Goals | Digital Millennium Copyright Act | Millennium Stadium | Millennium | Millennium (TV series) | Millennium Park | Millennium Challenge Corporation | millennium | Wales Millennium Centre | Millennium Centre | Millennium: Journal of International Studies | Millennium Falcon | Millennium Dome | Torrent Pharmaceuticals | Millennium Foundation | Emcure Pharmaceuticals | Dubai Millennium | Barr Pharmaceuticals | 2000 Years: The Millennium Concert | Valeant Pharmaceuticals | United Nations Millennium Project | The Millennium | Reata Pharmaceuticals | Millennium Way | Millennium Volunteers | Millennium Series | Millennium Seed Bank Project | Millennium Records | Millennium Pharmaceuticals | Millennium Green |
After co-discovering the Leptin gene with Jeffrey Friedman et al. in 1994, which involved a reverse genetic/positional cloning strategy to clone ob and db, Rudolph Leibel, working with collaborators at Millennium Pharmaceuticals and colleague Streamson Chua, confirmed cloning of the leptin receptor by demonstrating that an apparent leptin receptor cloned from a choroid plexus library using leptin as ligand, mapped to a physical map that included db and fa.